Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
Krystal Biotech Trading Up 3.9 %
Shares of KRYS traded up $2.91 during mid-day trading on Friday, reaching $77.32. The company had a trading volume of 1,875 shares, compared to its average volume of 157,684. The stock has a market cap of $1.98 billion, a price-to-earnings ratio of -16.38 and a beta of 0.88. The firm has a fifty day simple moving average of $69.47 and a 200-day simple moving average of $65.35. Krystal Biotech has a fifty-two week low of $38.86 and a fifty-two week high of $102.99.
Krystal Biotech (NASDAQ:KRYS - Get Rating) last announced its quarterly earnings results on Monday, August 8th. The company reported ($1.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.99) by ($0.11). As a group, equities analysts predict that Krystal Biotech will post -5.36 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
A number of research analysts have commented on KRYS shares. The Goldman Sachs Group decreased their price target on Krystal Biotech from $91.00 to $78.00 and set a "buy" rating on the stock in a research note on Tuesday, May 24th. Chardan Capital lowered their target price on shares of Krystal Biotech from $137.00 to $130.00 and set a "buy" rating for the company in a research note on Tuesday, August 9th.